Compare Gilead Sciences, Inc. (GILD) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tempus AI — how do they compare? Gilead Sciences, Inc. trades at $135.58 (market cap $163.51B), while Tempus AI trades at $52.78 (market cap $10.28B). The key difference: Gilead Sciences, Inc. is far larger — about 15.9× Tempus AI's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| GILD | TEM | |
|---|---|---|
Market Cap | $163.51B | $10.28B |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $103.25 |
52-Week Low | $108.22 | $42.37 |
Enterprise Value | $178.05B | $10.96B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Tempus AI (TEM) trades at $53.69, down 8.39% over 24 hours, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth ($1.27B in 2025) and consistent earnings beats, but remains unprofitable with negative net income margins (-22.2%). Recent news highlights AI deployment in healthcare systems and FDA clearances, supporting its data-driven healthcare platform.
The outlook balances high-growth potential in AI healthcare data against persistent profitability challenges. Analyst consensus is bullish with a $68.50 price target, but investors face risks from ongoing cash burn, competitive pressures, and execution hurdles as the company scales its platform toward sustainable margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
